GRI Bio, Inc. (GRI)
NASDAQ: GRI · Real-Time Price · USD
1.830
-0.060 (-3.17%)
At close: Nov 11, 2026, 4:00 PM EST
1.762
-0.068 (-3.69%)
After-hours: Nov 11, 2026, 5:44 PM EST
GRI Bio Employees
As of December 31, 2025, GRI Bio had 4 total employees, including 3 full-time and 1 part-time employees. The number of employees did not change compared to the previous year. That makes GRI Bio the 42,245th largest employer in the world and 6,643rd in the United States.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,414,750
Market Cap
4.00M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 4 | 0 | - | 3 | 1 |
| Dec 31, 2024 | 4 | 0 | - | 3 | 1 |
| Dec 31, 2023 | 4 | 3 | 300.00% | 4 | 0 |
| Dec 31, 2022 | 1 | - | - | 1 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Cerenome | 28 |
| NeuroSense Therapeutics | 17 |
| Azitra | 13 |
| NuCana | 12 |
| Traws Pharma | 7 |
| Ernexa Therapeutics | 7 |
| KALA BIO | 6 |
| Creative Medical Technology Holdings | 4 |
GRI News
- 7 days ago - GRI Bio Transcript: AGM 2026 - Transcripts
- 4 weeks ago - Bristol Phase 3 win underscores opportunity for GRI Bio, says H.C. Wainwright - TheFly
- 6 weeks ago - GRI Bio to highlight immune modulation, Phase 2a development at IPF Summit - TheFly
- 6 weeks ago - GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit - GlobeNewsWire
- 6 weeks ago - GRI Bio Proxy statement: Proxy filing - Filings
- 2 months ago - GRI Bio announces new translational biomarker data from GRI-0621-IPF-02 study - TheFly
- 2 months ago - GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars - GlobeNewsWire
- 2 months ago - GRI Bio Featured in "Why Now" On-Demand Video Webcast - GlobeNewsWire